New treatment and management options for adult acute lymphocytic leukemia (ALL).
| Molecular therapy |
| • Direct inhibition of molecular aberrations involved in pathogenesis |
| → tyrosine kinase inhibitor STI571, farnesyl transferase inhibitors |
| Antibody therapy |
| • Targeted suppression of leukemic blasts according to surface antigen expression |
| → see Table 5 |
| Non-myeloablative stem cell transplantation |
| • Utilization of graft-versus-leukemia effects |
| → Extension of stem cell transplantation indications to elderly/comorbid patients |
| Minimal residual disease evaluation |
| • Individual evaluation of treatment response |
| → Assessment of therapy elements, e.g., induction, novel therapeutics and risk stratification |
| Microarray analysis |
| • Analysis of gene expression profiles and selection of differentially expressed genes |
| → Identification of prognostic factors and target genes for novel therapeutics |
| Molecular therapy |
| • Direct inhibition of molecular aberrations involved in pathogenesis |
| → tyrosine kinase inhibitor STI571, farnesyl transferase inhibitors |
| Antibody therapy |
| • Targeted suppression of leukemic blasts according to surface antigen expression |
| → see Table 5 |
| Non-myeloablative stem cell transplantation |
| • Utilization of graft-versus-leukemia effects |
| → Extension of stem cell transplantation indications to elderly/comorbid patients |
| Minimal residual disease evaluation |
| • Individual evaluation of treatment response |
| → Assessment of therapy elements, e.g., induction, novel therapeutics and risk stratification |
| Microarray analysis |
| • Analysis of gene expression profiles and selection of differentially expressed genes |
| → Identification of prognostic factors and target genes for novel therapeutics |